NeuroMetrix, Inc. Stock price

Equities

NURO

US6412558800

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 02:18:35 2024-03-28 pm EDT 5-day change 1st Jan Change
4.15 USD -0.24% Intraday chart for NeuroMetrix, Inc. +1.97% +15.28%
Sales 2022 8.26M Sales 2023 5.9M Capitalization 3.87M
Net income 2022 -4M Net income 2023 -6M EV / Sales 2022 -1.12 x
Net cash position 2022 20.84M Net cash position 2023 17.76M EV / Sales 2023 -2.35 x
P/E ratio 2022
-2.41 x
P/E ratio 2023
-0.57 x
Employees 26
Yield 2022 *
-
Yield 2023
-
Free-Float 84.06%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.00%
1 week+7.49%
Current month+2.46%
1 month+12.74%
3 months+9.91%
6 months-14.33%
Current year+15.56%
More quotes
1 week
4.00
Extreme 4
4.19
1 month
3.58
Extreme 3.5816
4.30
Current year
2.70
Extreme 2.7
4.42
1 year
2.70
Extreme 2.7
12.04
3 years
2.70
Extreme 2.7
310.00
5 years
2.70
Extreme 2.7
310.00
10 years
2.70
Extreme 2.7
8 064.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 96-05-31
Director of Finance/CFO 72 09-09-09
Corporate Officer/Principal - 22-01-09
Members of the board TitleAgeSince
Director/Board Member 65 10-12-16
Director/Board Member 67 04-05-31
Chief Executive Officer 59 96-05-31
More insiders
Date Price Change Volume
24-03-28 4.15 -0.24% 3 706
24-03-27 4.16 +4.00% 2,753
24-03-26 4 -1.96% 6,415
24-03-25 4.08 -1.69% 16,159
24-03-22 4.15 +1.97% 15,572

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
NeuroMetrix, Inc. is a commercial-stage neurotechnology company based in Woburn, Massachusetts. The Company is engaged in designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The Company has two principal product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. The Company's DPNCheck is its testing technology for peripheral neuropathies. The Company's Quell is its wearable neuromodulation technology for chronic pain. It refined approximately 200,000 chronic pain patients. Patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
More about the company
  1. Stock
  2. Equities
  3. Stock NeuroMetrix, Inc. - Nasdaq